Symbol not found

NASDAQ:SRNE   00:00AM GMT
0.00
0.00 (0.00%)
Products

Sorrento Completes Successfully SAD Study And Initiates MAD Phase 1 Study With STI-1558

Published: 08/03/2022 13:18 GMT
Sorrento Therapeutics Inc (SRNE) - Sorrento Completes Successfully the Sad Study and Initiates the Mad Phase 1 Study With Sti-1558, an Oral M(pro) Inhibitor As a Standalone Treatment and Prevention of Covid-19 Without the Ritonavir As Booster.
Sorrento Therapeutics Inc- Initiation of Multiple Ascending Dose (mad) Portion of Sti-1558 Study Has Been Initiated.
Sorrento Therapeutics Inc- Preliminary Overall Summary of Treatment-emergent Adverse Events Showed That There Were No Serious Aes Or Severe Teaes.